References
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18): 1371–88
- Dawson DA, Thompson GB. Breast cancer risk factors and screening: United States, 1987. Hyattsville, Md: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Health Statistics, 1990 (Vital and health statistics. Series 10); DHHS publication No. (PHS) 90–1500
- Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352(9122): 93–7
- Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352(9122): 98–101
- Gradishar WJ, Jordan VC. Endocrine therapy of breast cancer. In: Bland KI, Copeland EM 3d, eds. The breast: comprehensive management of benign and malignant diseases. 2d ed. Philadelphia: Saunders, 1998: 1350–72
- Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13(2): 513–29
- Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88(21): 1529–42
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351(9114): 1451–67
- Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16(2): 239–51
- Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81(24):1879–86
- Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 1985; 55(11): 2698–708
- Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCAI and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277(12): 997–1003
- Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. ? Engl J Med 1999; 340(2): 77–84
- Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85(17): 1398–406
- McDonald CC, Alexander FE, Whyte BW, et al, for the Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995; 311(7011): 977–80
- Grady D, Sawaya G. Postmenopausal hormone therapy increases risk of deep vein thrombosis and pulmonary embolism. Am J Med 1998; 105(1): 41–3
- Dunn N, de Caestecker L, Bigrigg A. Oral contraceptives and thrombosis. Curr Opin Obstet Gynecol 1998; 10(3): 205–9
- England GM, Jordan VC. Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997; 9(8): 397–402
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7
- Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. (Abstr) Breast Cancer Res Treat 1998; 50(30)
- Evista package insert. Eli Lilly and Company, Dec 1997